IL113159A0 - Synthetic peptides and pharmaceutical compositions comprising them - Google Patents

Synthetic peptides and pharmaceutical compositions comprising them

Info

Publication number
IL113159A0
IL113159A0 IL11315995A IL11315995A IL113159A0 IL 113159 A0 IL113159 A0 IL 113159A0 IL 11315995 A IL11315995 A IL 11315995A IL 11315995 A IL11315995 A IL 11315995A IL 113159 A0 IL113159 A0 IL 113159A0
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
peptides
synthetic peptides
peptide
sle
Prior art date
Application number
IL11315995A
Other languages
English (en)
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Priority to IL11315995A priority Critical patent/IL113159A0/xx
Publication of IL113159A0 publication Critical patent/IL113159A0/xx
Priority to US08/913,994 priority patent/US6613536B1/en
Priority to DE69630682T priority patent/DE69630682T2/de
Priority to DK96911449T priority patent/DK0817650T3/da
Priority to JP52962296A priority patent/JP3862752B2/ja
Priority to AU54334/96A priority patent/AU706772B2/en
Priority to PCT/US1996/004206 priority patent/WO1996030057A1/en
Priority to IL11768696A priority patent/IL117686A/xx
Priority to PT96911449T priority patent/PT817650E/pt
Priority to AT96911449T priority patent/ATE253944T1/de
Priority to ES96911449T priority patent/ES2212801T3/es
Priority to EP96911449A priority patent/EP0817650B1/en
Priority to CA002217776A priority patent/CA2217776C/en
Priority to US10/620,621 priority patent/US20040235729A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL11315995A 1995-03-28 1995-03-28 Synthetic peptides and pharmaceutical compositions comprising them IL113159A0 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
IL11315995A IL113159A0 (en) 1995-03-28 1995-03-28 Synthetic peptides and pharmaceutical compositions comprising them
CA002217776A CA2217776C (en) 1995-03-28 1996-03-27 Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
PCT/US1996/004206 WO1996030057A1 (en) 1995-03-28 1996-03-27 Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
DE69630682T DE69630682T2 (de) 1995-03-28 1996-03-27 Synthetische peptide und diese enthaltende arzneimittel zur behandlung des systemischen lupus erythematodes
DK96911449T DK0817650T3 (da) 1995-03-28 1996-03-27 Syntetiske peptider og farmaceutiske sammensætninger, der omfatter disse, til behandling af systemisk lupus erythematosus
JP52962296A JP3862752B2 (ja) 1995-03-28 1996-03-27 全身性エリテマトーデス治療用の合成ベプチドおよびこれを含有する薬剤組成物
AU54334/96A AU706772B2 (en) 1995-03-28 1996-03-27 Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
US08/913,994 US6613536B1 (en) 1995-03-28 1996-03-27 Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
IL11768696A IL117686A (en) 1995-03-28 1996-03-27 Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
PT96911449T PT817650E (pt) 1995-03-28 1996-03-27 Peptidos sinteticos e composicoes farmaceuticas que os contem para o tratamento do lupus eritematoso sistemico
AT96911449T ATE253944T1 (de) 1995-03-28 1996-03-27 Synthetische peptide und diese enthaltende arzneimittel zur behandlung des systemischen lupus erythematodes
ES96911449T ES2212801T3 (es) 1995-03-28 1996-03-27 Peptidos sinteticos y composiciones farmaceuticas que los contienen para el tratamiento del lupus eritematoso sistemico.
EP96911449A EP0817650B1 (en) 1995-03-28 1996-03-27 Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
US10/620,621 US20040235729A1 (en) 1995-03-28 2003-07-17 Synthethic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL11315995A IL113159A0 (en) 1995-03-28 1995-03-28 Synthetic peptides and pharmaceutical compositions comprising them

Publications (1)

Publication Number Publication Date
IL113159A0 true IL113159A0 (en) 1995-06-29

Family

ID=11067281

Family Applications (2)

Application Number Title Priority Date Filing Date
IL11315995A IL113159A0 (en) 1995-03-28 1995-03-28 Synthetic peptides and pharmaceutical compositions comprising them
IL11768696A IL117686A (en) 1995-03-28 1996-03-27 Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL11768696A IL117686A (en) 1995-03-28 1996-03-27 Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus

Country Status (11)

Country Link
EP (1) EP0817650B1 (pt)
JP (1) JP3862752B2 (pt)
AT (1) ATE253944T1 (pt)
AU (1) AU706772B2 (pt)
CA (1) CA2217776C (pt)
DE (1) DE69630682T2 (pt)
DK (1) DK0817650T3 (pt)
ES (1) ES2212801T3 (pt)
IL (2) IL113159A0 (pt)
PT (1) PT817650E (pt)
WO (1) WO1996030057A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613536B1 (en) * 1995-03-28 2003-09-02 Yeda Research And Development Co. Ltd. Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
JP3820105B2 (ja) 1998-10-23 2006-09-13 キリン−アムジエン・インコーポレーテツド Ｍｐ１受容体に結合し血小板生成活性を有する二量体トロンボポエチンペプチド模倣体
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
IL141647A0 (en) 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
EP1511772B1 (en) 2002-05-28 2011-11-23 Omrix Biopharmaceuticals Inc. Method for obtaining anti-idiotype antibodies
US7294687B2 (en) * 2003-01-14 2007-11-13 Teva Pharmaceutical Industries, Ltd. Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus
AU2004206842A1 (en) * 2003-01-14 2004-08-05 Teva Pharmaceutical Industries, Ltd. Parenteral formulations of peptides for the treatment of systemic lupus erythematosus
EP1773400A2 (en) 2004-07-08 2007-04-18 Amgen Inc. Therapeutic peptides
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021367A1 (en) * 1991-05-31 1992-12-10 Arthur Allen Vandenbark T cell receptor peptides as therapeutics for immune-related disease

Also Published As

Publication number Publication date
AU706772B2 (en) 1999-06-24
DE69630682D1 (de) 2003-12-18
JP3862752B2 (ja) 2006-12-27
AU5433496A (en) 1996-10-16
IL117686A (en) 2000-10-31
CA2217776A1 (en) 1996-10-03
CA2217776C (en) 2004-12-07
EP0817650B1 (en) 2003-11-12
DK0817650T3 (da) 2004-03-08
EP0817650A1 (en) 1998-01-14
EP0817650A4 (en) 1999-09-01
PT817650E (pt) 2004-03-31
DE69630682T2 (de) 2004-09-16
ATE253944T1 (de) 2003-11-15
ES2212801T3 (es) 2004-08-01
IL117686A0 (en) 1996-07-23
WO1996030057A1 (en) 1996-10-03
JPH11503124A (ja) 1999-03-23

Similar Documents

Publication Publication Date Title
CY1107708T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης
SG55079A1 (en) Multivalent single chain antibodies
TNSN93012A1 (fr) Conception, clonage et expression d'anticorps monoclonaux humanises contre l'interleukine-5 humaine
IL113159A0 (en) Synthetic peptides and pharmaceutical compositions comprising them
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
EA200100698A1 (ru) Моноклональные антитела человека к ctla-4
HK1048831A1 (en) Human ctla-4 antibodies and their uses
WO1998057994A3 (en) Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
EP2287190A3 (en) Human IGM antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
GR3020610T3 (en) Monoclonal antibodies against tumor associated antigen, their preparation and use
WO2004064787A3 (en) Parenteral formulations of peptides for the treatment of systemic lupus erythematosus
DK0845998T3 (da) Lægemidler til immunbehandling indeholdende antistoffer, der specifikt genkender MHCII-antigenet hos en patient, der skal behandles
EP0770624A3 (en) Peptide capable of inducing immune response to human gastric cancer and agent containing it for preventing or treating human gastric cancer
ES2127531T3 (es) Medicamento para la inmunosupresion prolongada y la eliminacion de celulas tumorales.
FR2718451B1 (fr) Dérivés de peptides boroniques, leur préparation et leur application en thérapeutique.
NO922621D0 (no) Farmasoeytiske preparater inneholdende antigen-antistoffkomplekser og anvendelser derav
IL98769A (en) Synthetic peptides, mixtures thereof, methods utilizing the same for detecting hiv antibodies and pharmaceutical compositions containing the same
WO2000001729A3 (en) Synthetic peptides and pharmaceutical compositions comprising them for diagnosis and treatment of anti-phospholipid syndrome
EA199900260A1 (ru) Кристаллический фармацевтический продукт
DE69607962D1 (de) Synthetische peptide und diese enthaltende pharmazeutische zusammensetzungen
FR2694938B1 (fr) Nouveaux peptides, anticorps diriges contre ces peptides, anticorps anti-idiotypiques, application a titre de medicaments, compositions pharmaceutiques et kits de diagnostic les renfermant.
PT951481E (pt) Utilizacao de substancias com accao imunomoduladora para o tratamento da esclerose lateral amiotrofica
AU653332B2 (en) Synthetic peptides which contain sequences from factor VIIa, and the use thereof
AU3283693A (en) Specific antibodies against activated platelets, the preparation thereof and the use thereof in diagnosis and therapy
Hochkeppel et al. Delivery of Interferons to Target Cells by Monoclonal Antibodies: Potential for the Specific Targeting of Other Lymphokines